ALTG 15/001 TD 13.03 SABR-OS: A randomised phase II trial to test the feasibility of randomising patients with peripheral stage I non-small cell lung cancer to either Stereotactic Ablative Radiotherapy (SABR) Or Surgery – F Hegi-Johnson
This trial was initially submitted as an international collaborative group phase II study titled SABRTOOTH however, during 2014 it was recognised that, due to differences in the timing of funding and governance between the UK and Australia, a standalone Australian protocol would need to be developed. As a result, the SABR-OS phase II study was approved for development by the TROG Scientific committee in February 2015 (with ALTG collaboration). It was anticipated that the SABRTOOTH and SABR-OS trials will proceed to a join international phase III trial.
The SABR-OS trial will aim to assess the feasibility of recruiting patients, with histologically confirmed peripheral stage I NSCLC who are at higher risk of mortality and morbidity after surgery, into trial that randomises between multi-fraction Stereotactic Ablative Body Radiotherapy (SABR) and surgery (lobectomy or sub-lobar resection).
Disease free and overall survival, toxicity and selected patient-reported outcomes will be assessed as secondary endpoints. An economic evaluation will also be included in the study design. The study of patient preferences using Discrete Choice Experiment (DCE) has begun. In collaboration with CREST, a consumer meeting regarding the design and implementation of the consumer survey has been conducted and the DCE survey is being prepared.
Trial Chair: Dr Fiona Hegi-Johnson email@example.com
Trail Coordinator: Angie Chung, TROG Cancer Research SABR-OS@trog.com.au